{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T03:26:49Z","timestamp":1771471609778,"version":"3.50.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,4,30]],"date-time":"2022-04-30T00:00:00Z","timestamp":1651276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,4,30]],"date-time":"2022-04-30T00:00:00Z","timestamp":1651276800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"iNOVA4Health","award":["UIDB\/04462\/2020"],"award-info":[{"award-number":["UIDB\/04462\/2020"]}]},{"name":"iNOVA4Health","award":["UIDB\/04462\/2020"],"award-info":[{"award-number":["UIDB\/04462\/2020"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Cell Int"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Epithelial ovarian cancer (EOC) is an aggressive and lethal malignancy and novel EOC cell lines with detailed characterization are needed, to provide researchers with diverse helpful resources to study EOC biological processes and cancer experimental therapies.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>The IPO43 cell line was established from the ascitic fluid of a patient with a diagnosis of high-grade serous carcinoma (HGSC) of the ovary, previously treated with chemotherapy.<\/jats:p>\n                <jats:p>Cell immortalization was achieved in 2D cell culture and growth obtained in 2D and 3D cell cultures. The characterization of immortalized cells was done by immunocytochemistry, flow cytometry, cell proliferation, chromosomal Comparative Genomic Hybridization (cCGH), STR profile and Next Generation Sequencing (NGS).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Characterization studies confirmed that IPO43 cell line is of EOC origin and maintains morphological and molecular features of the primary tumor. cCGH analysis showed a complex profile with gains and losses of specific DNA regions in both primary ascitic fluid and cell\u00a0line IPO43. The cell line was successfully grown in a 3D system which allows its future application in more complex assays than those performed in 2D models. IPO43 cell line is resistant to standard drug treatment in vitro.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>IPO43 is available for public research and we hope it can contribute to enrich the in vitro models addressing EOC heterogeneity, being useful to investigate EOC and to develop new therapeutic modalities.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12935-022-02600-3","type":"journal-article","created":{"date-parts":[[2022,5,2]],"date-time":"2022-05-02T13:12:13Z","timestamp":1651497133000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Establishment and characterization of a novel ovarian high-grade serous carcinoma cell line\u2014IPO43"],"prefix":"10.1186","volume":"22","author":[{"given":"Fernanda","family":"Silva","sequence":"first","affiliation":[]},{"given":"Filipa","family":"Coelho","sequence":"additional","affiliation":[]},{"given":"Ana","family":"Peixoto","sequence":"additional","affiliation":[]},{"given":"Pedro","family":"Pinto","sequence":"additional","affiliation":[]},{"given":"Carmo","family":"Martins","sequence":"additional","affiliation":[]},{"given":"Ann-Sophie","family":"Frombach","sequence":"additional","affiliation":[]},{"given":"V\u00edtor E.","family":"Santo","sequence":"additional","affiliation":[]},{"given":"Catarina","family":"Brito","sequence":"additional","affiliation":[]},{"given":"Ant\u00f3nio","family":"Guimar\u00e3es","sequence":"additional","affiliation":[]},{"given":"Ana","family":"F\u00e9lix","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2022,4,30]]},"reference":[{"key":"2600_CR1","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1517\/17460440902821657","volume":"4","author":"G Feldmann","year":"2009","unstructured":"Feldmann G, Rauenzahn S, Maitra A. In vitro models of pancreatic cancer for translational oncology research. Expert Opin Drug Discov. 2009;4:429\u201343.","journal-title":"Expert Opin Drug Discov"},{"key":"2600_CR2","doi-asserted-by":"publisher","first-page":"1600505","DOI":"10.1002\/biot.201600505","volume":"12","author":"VE Santo","year":"2017","unstructured":"Santo VE, Rebelo SP, Estrada MF, Alves PM, Boghaert E, Brito C. Drug screening in 3D in vitro tumor models: overcoming current pitfalls of efficacy read-outs. Biotechnol J. 2017;12:1600505. https:\/\/doi.org\/10.1002\/biot.201600505.","journal-title":"Biotechnol J"},{"key":"2600_CR3","doi-asserted-by":"publisher","first-page":"e103988","DOI":"10.1371\/journal.pone.0103988","volume":"9","author":"CM Beaufort","year":"2014","unstructured":"Beaufort CM, Helmijr JCA, Piskorz AM, Hoogstraat M, Ruigrok-Ritstier K, Besselink N, et al. Ovarian cancer cell line panel (OCCP): clinical importance of in vitro morphological subtypes. PLoS ONE. 2014;9:e103988.","journal-title":"PLoS ONE"},{"key":"2600_CR4","doi-asserted-by":"publisher","first-page":"2617","DOI":"10.1016\/j.celrep.2018.10.096","volume":"25","author":"E Papp","year":"2018","unstructured":"Papp E, Hallberg D, Konecny GE, Bruhm DC, Adleff V, No\u00eb M, et al. Integrated genomic, epigenomic, and expression analyses of ovarian cancer cell lines. Cell Rep. 2018;25:2617\u201333.","journal-title":"Cell Rep"},{"key":"2600_CR5","doi-asserted-by":"publisher","first-page":"2126","DOI":"10.1038\/ncomms3126","volume":"4","author":"S Domcke","year":"2013","unstructured":"Domcke S, Sinha R, Levine DA, Sander C, Schultz N. Evaluating cell lines as tumour models by comparison of genomic profiles. Nat Commun. 2013;4:2126.","journal-title":"Nat Commun"},{"key":"2600_CR6","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1038\/bjc.2013.126","volume":"108","author":"DSP Tan","year":"2013","unstructured":"Tan DSP, Miller RE, Kaye SB. New perspectives on molecular targeted therapy in ovarian clear cell carcinoma. Br J Cancer. 2013;108:1553\u20139. https:\/\/doi.org\/10.1038\/bjc.2013.126.","journal-title":"Br J Cancer"},{"key":"2600_CR7","doi-asserted-by":"publisher","DOI":"10.1177\/1179299X19860815","author":"R Pokhriyal","year":"2019","unstructured":"Pokhriyal R, Hariprasad R, Kumar L, Hariprasad G. Chemotherapy resistance in advanced ovarian cancer patients. Biomark Cancer. 2019. https:\/\/doi.org\/10.1177\/1179299X19860815.","journal-title":"Biomark Cancer."},{"key":"2600_CR8","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1038\/nrc1123","volume":"3","author":"R Agarwal","year":"2003","unstructured":"Agarwal R, Kaye SB. Ovarian cancer: strategies for overcoming resistance to chemotherapy. Nat Rev Cancer. 2003;3:502\u201316.","journal-title":"Nat Rev Cancer"},{"key":"2600_CR9","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1002\/gcc.2870100403","volume":"10","author":"OP Kallioniemi","year":"1994","unstructured":"Kallioniemi OP, Kallioniemi A, Piper J, Isola J, Waldman FM, Gray JW, et al. Optimizing comparative genomic hybridization for analysis of DNA sequence copy number changes in solid tumors. Genes Chromosomes Cancer. 1994;10:231\u201343.","journal-title":"Genes Chromosomes Cancer"},{"key":"2600_CR10","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1002\/gcc.10146","volume":"36","author":"L Roque","year":"2003","unstructured":"Roque L, Rodrigues R, Pinto A, Moura-Nunes V, Soares J. Chromosome imbalances in thyroid follicular neoplasms: a comparison between follicular adenomas and carcinomas. Genes Chromosomes Cancer. 2003;36:292\u2013302.","journal-title":"Genes Chromosomes Cancer"},{"key":"2600_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jbiotec.2016.01.031","volume":"221","author":"VE Santo","year":"2016","unstructured":"Santo VE, Estrada MF, Rebelo SP, Abreu S, Silva I, Pinto C, et al. Adaptable stirred-tank culture strategies for large scale production of multicellular spheroid-based tumor cell models. J Biotechnol. 2016;221:1\u201312.","journal-title":"J Biotechnol"},{"key":"2600_CR12","volume-title":"Methods in molecular biology","author":"G Cory","year":"2011","unstructured":"Cory G. Cell migration. In: Wells CM, Parsons M, editors. Methods in molecular biology. Totowa, NJ: Humana Press; 2011."},{"key":"2600_CR13","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1038\/nature10166","volume":"474","author":"Cancer Genome Atlas Research Network","year":"2011","unstructured":"Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature. 2011;474:609\u201315.","journal-title":"Nature"},{"key":"2600_CR14","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1002\/gcc.2870040108","volume":"4","author":"T Pejovic","year":"1992","unstructured":"Pejovic T, Heim S, Mitelman F, Mandahl N, Flod\u00e9rus U-M, Furgyik S, et al. Chromosome aberrations in 35 primary ovarian carcinomas. Genes, Chromosom Cancer. 1992;4:58\u201368. https:\/\/doi.org\/10.1002\/gcc.2870040108.","journal-title":"Genes, Chromosom Cancer"},{"key":"2600_CR15","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1038\/ng.666","volume":"42","author":"KL Bolton","year":"2010","unstructured":"Bolton KL, Tyrer J, Song H, Ramus SJ, Notaridou M, Jones C, et al. Common variants at 19p13 are associated with susceptibility to ovarian cancer. Nat Genet. 2010;42:880\u20134.","journal-title":"Nat Genet"},{"key":"2600_CR16","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1093\/jnci\/djj245","volume":"98","author":"BJ Boersma","year":"2006","unstructured":"Boersma BJ, Howe TM, Goodman JE, Yfantis HG, Lee DH, Chanock SJ, et al. Association of breast cancer outcome with status of p53 and MDM2 SNP309. JNCI J Natl Cancer Inst. 2006;98:911\u20139.","journal-title":"JNCI J Natl Cancer Inst"},{"key":"2600_CR17","doi-asserted-by":"crossref","unstructured":"Berg M, Danielsen SA, Ahlquist T, Merok MA, \u00c5gesen TH, Vatn MH, et al. DNA sequence profiles of the colorectal cancer critical gene set KRAS-BRAF-PIK3CA-PTEN-TP53 related to age at disease onset. Chan KYK, editor. PLoS One 2010;5:e13978.","DOI":"10.1371\/journal.pone.0013978"},{"key":"2600_CR18","first-page":"671","volume":"6","author":"G Aquilina","year":"2000","unstructured":"Aquilina G, Ceccotti S, Martinelli S, Soddu S, Crescenzi M, Branch P, et al. Mismatch repair and p53 independently affect sensitivity to N-(2-chloroethyl)-N\u2032-cyclohexyl-N-nitrosourea. Clin Cancer Res. 2000;6:671\u201380.","journal-title":"Clin Cancer Res"},{"key":"2600_CR19","first-page":"698","volume":"58","author":"ZH Siddik","year":"1998","unstructured":"Siddik ZH, Mims B, Lozano G, Thai G. Independent pathways of p53 induction by cisplatin and X-rays in a cisplatin-resistant ovarian tumor cell line. Cancer Res. 1998;58:698\u2013703.","journal-title":"Cancer Res"},{"key":"2600_CR20","doi-asserted-by":"publisher","first-page":"40115","DOI":"10.18632\/oncotarget.9499","volume":"7","author":"M Zanjirband","year":"2016","unstructured":"Zanjirband M, Edmondson RJ, Lunec J. Pre-clinical efficacy and synergistic potential of the MDM2-p53 antagonists, Nutlin-3 and RG7388, as single agents and in combined treatment with cisplatin in ovarian cancer. Oncotarget. 2016;7:40115\u201334.","journal-title":"Oncotarget"},{"key":"2600_CR21","doi-asserted-by":"publisher","first-page":"4798","DOI":"10.1038\/onc.2016.12","volume":"35","author":"X Xie","year":"2016","unstructured":"Xie X, Lozano G, Siddik ZH. Heterozygous p53V172F mutation in cisplatin-resistant human tumor cells promotes MDM4 recruitment and decreases stability and transactivity of p53. Oncogene. 2016;35:4798\u2013806.","journal-title":"Oncogene"},{"key":"2600_CR22","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/S0378-1119(01)00696-5","volume":"277","author":"C Cadwell","year":"2001","unstructured":"Cadwell C, Zambetti GP. The effects of wild-type p53 tumor suppressor activity and mutant p53 gain-of-function on cell growth. Gene. 2001;277:15\u201330.","journal-title":"Gene"},{"key":"2600_CR23","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/1757-2215-7-60","volume":"7","author":"F Jacob","year":"2014","unstructured":"Jacob F, Nixdorf S, Hacker NF, Heinzelmann-Schwarz VA. Reliable in vitro studies require appropriate ovarian cancer cell lines. J Ovarian Res. 2014;7:60.","journal-title":"J Ovarian Res"},{"key":"2600_CR24","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1016\/S0002-9440(10)63708-X","volume":"164","author":"I-M Shih","year":"2004","unstructured":"Shih I-M, Kurman RJ. Ovarian tumorigenesis. Am J Pathol. 2004;164:1511\u20138.","journal-title":"Am J Pathol"},{"key":"2600_CR25","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1097\/PGP.0b013e3181c042b6","volume":"29","author":"M K\u00f6bel","year":"2010","unstructured":"K\u00f6bel M, Kalloger SE, Huntsman DG, Santos JL, Swenerton KD, Seidman JD, et al. Differences in tumor type in low-stage versus high-stage ovarian carcinomas. Int J Gynecol Pathol. 2010;29:203\u201311.","journal-title":"Int J Gynecol Pathol"},{"key":"2600_CR26","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1002\/ijc.27711","volume":"132","author":"F Bray","year":"2013","unstructured":"Bray F, Ren J-SS, Masuyer E, Ferlay J. Global estimates of cancer prevalence for 27 sites in the adult population in 2008. Int J Cancer. 2013;132:1133\u201345.","journal-title":"Int J Cancer"},{"key":"2600_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/gcc.20384","volume":"46","author":"SW Kim","year":"2007","unstructured":"Kim SW, Kim JW, Kim YT, Kim JH, Kim S, Yoon BS, et al. Analysis of chromosomal changes in serous ovarian carcinoma using high-resolution array comparative genomic hybridization: potential predictive markers of chemoresistant disease. Genes Chromosomes Cancer. 2007;46:1\u20139.","journal-title":"Genes Chromosomes Cancer"},{"key":"2600_CR28","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646\u201374.","journal-title":"Cell"},{"key":"2600_CR29","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1186\/1471-2407-14-315","volume":"14","author":"F Micci","year":"2014","unstructured":"Micci F, Haugom L, Abeler VM, Davidson B, Trop\u00e9 CG, Heim S. Genomic profile of ovarian carcinomas. BMC Cancer. 2014;14:315.","journal-title":"BMC Cancer"},{"key":"2600_CR30","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1002\/gcc.20813","volume":"49","author":"F Micci","year":"2010","unstructured":"Micci F, Skotheim RI, Haugom L, Weimer J, Eibak AME, Abeler VM, et al. Array-CGH analysis of microdissected chromosome 19 markers in ovarian carcinoma identifies candidate target genes. Genes Chromosom Cancer. 2010;49:1046\u201353. https:\/\/doi.org\/10.1002\/gcc.20813.","journal-title":"Genes Chromosom Cancer"},{"key":"2600_CR31","doi-asserted-by":"publisher","first-page":"279","DOI":"10.3390\/diagnostics10050279","volume":"10","author":"JW Gorski","year":"2020","unstructured":"Gorski JW, Ueland FR, Kolesar JM. CCNE1 amplification as a predictive biomarker of chemotherapy resistance in epithelial ovarian cancer. Diagnostics. 2020;10:279.","journal-title":"Diagnostics"},{"key":"2600_CR32","doi-asserted-by":"publisher","first-page":"9167","DOI":"10.1038\/srep09167","volume":"5","author":"GSL Peh","year":"2015","unstructured":"Peh GSL, Adnan K, George BL, Ang H-P, Seah X-Y, Tan DT, et al. The effects of Rho-associated kinase inhibitor Y-27632 on primary human corneal endothelial cells propagated using a dual media approach. Sci Rep. 2015;5:9167.","journal-title":"Sci Rep"},{"key":"2600_CR33","doi-asserted-by":"publisher","first-page":"1971","DOI":"10.1007\/s11033-009-9645-9","volume":"37","author":"L Wang","year":"2010","unstructured":"Wang L, Xue L, Yan H, Li J, Lu Y. Effects of ROCK inhibitor, Y-27632, on adhesion and mobility in esophageal squamous cell cancer cells. Mol Biol Rep. 2010;37:1971\u20137.","journal-title":"Mol Biol Rep"},{"key":"2600_CR34","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.biomaterials.2015.11.030","volume":"78","author":"MF Estrada","year":"2016","unstructured":"Estrada MF, Rebelo SP, Davies EJ, Pinto MT, Pereira H, Santo VE, et al. Modelling the tumour microenvironment in long-term microencapsulated 3D co-cultures recapitulates phenotypic features of disease progression. Biomaterials. 2016;78:50\u201361.","journal-title":"Biomaterials"}],"container-title":["Cancer Cell International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12935-022-02600-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12935-022-02600-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12935-022-02600-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,2]],"date-time":"2022-05-02T13:17:11Z","timestamp":1651497431000},"score":1,"resource":{"primary":{"URL":"https:\/\/cancerci.biomedcentral.com\/articles\/10.1186\/s12935-022-02600-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,30]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["2600"],"URL":"https:\/\/doi.org\/10.1186\/s12935-022-02600-3","relation":{},"ISSN":["1475-2867"],"issn-type":[{"value":"1475-2867","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,30]]},"assertion":[{"value":"4 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 April 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical permission for the study was approved by the Ethics Committee of IPOLFG (UIC-772). Informed consent was obtained from the patient included in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval and Consent to participate"}},{"value":"The authors declare that they have no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"175"}}